Spry's are established modifiers of receptor tyrosine kinase (RTK) signaling, and play important roles in vasculogenesis, bone morphogenesis, and renal uteric branching. Little is understood, however, concerning possible roles for these molecular adaptors during hematopoiesis. Within erythroid lineage, Spry1 was observed to be selectively and highly expressed at CFU-e to erythroblast stages. In analyses of possible functional roles, an Mx1-Cre approach was applied to conditionally delete Spry1. At steady-state, Spry1-deletion selectively perturbed erythroid development, and led to reticulocytosis plus heightened splenic erythropoiesis. When challenged by hemolysis, Spry1-null mice exhibited worsened anemia, and delayed recovery. During short-term marrow transplantation, Spry1-null donor marrow also failed to efficiently rescue the erythron. In each anemia model, however, hyper-expansion of erythroid progenitors was observed. Spry function depends upon phosphorylation of a conserved N-terminal PY motif. Through an LC-MS/MS approach, Spry1 was discovered to be regulated via the erythropoietin receptor (EPOR), with marked EPO-induced Spry1-PY53 phosphorylation observed. When EPOR signaling pathways were analyzed within Spry1-deficient erythroid progenitors, hyperactivation of not only Erk1,2 but also Jak2 was observed. Studies implicate Spry1 as a novel regulator of erythropoiesis during anemia; transducer of EPOR signals; and candidate suppressor of Jak2 activity.
INTRODUCTION
Sprouty proteins (or Spry's) are best known as receptor tyrosine kinase-(RTK) activated modulators of FGF and EGF signaling [1] [2] [3] . Drosophila Sprouty (dSprouty) first was described as an FGFR antagonist, and modulator of apical branching within embryonic airways 4 . For dSprouty, negative-feedback roles within EGFR and Torso receptor tyrosine kinase (RTK) systems also have been described (with Gap as one implicated target) 5 . Within vertebrates, four Spry's have evolved [1] [2] [3] . This provides capacities for extended effects via varied spatial-temporal expression among tissues, and via interactions with alternate molecular partners. One recent illustration is provided by dysregulation due to Spry2 disruption of diastema formation during tooth development 6 . In this context, epithelial Spry2 plus mesenchymal Spry4 act in concert to enforce FGF refractivity, and tooth bud regression.
With regards to molecular mechanisms that support the effects of Spry's, several studies emphasize negative actions on a Ras/Raf/Mek/Erk axis. Here, Raf is one prime candidate target for Spry binding 7 . As recently studied in a T-cell receptor context, this also may involve Spry effects on PLC-gamma 8 . In Xenopus, such actions of Spry's have been extended to include regulation of the duration of ERK signaling, and consequentially dorsoventral patterning 9 . Another candidate target for Spry's is PTEN. In particular, levels of this phosphoinositide phosphatase are increased upon ectopic Spry2 expression, with accompanying observed decreases in Akt activation 10 . Notably, Spry's also can exert apparent positive roles. This is perhaps best characterized in the EGFR system, and one mechanism involves Spry2 binding and sequestration of the E3 ubiquitin ligase, Cbl 11 . When Cbl is sequestered, EGFR ubiquitinylation and turnover is attenuated, and signaling is sustained 12 . Underlying these diverse effects of Spry proteins are several major structural features [1] [2] [3] . These include an essential N-terminal PY motif for RTK/PTK mediated phosphorylation (as well as
Cbl and PTK binding); a regulatory serine-rich motif; and a C-terminal cysteine-rich domain which mediates plasma membrane translocation, and also encodes proposed docking sites for several co-factors including Grb2 and Shp protein tyrosine phosphatases 3, 13, 14 .
For personal use only. on April 23, 2017 . by guest www.bloodjournal.org From Within hematopoietic contexts, comparably little attention has been paid to possible roles for Spry's. This is despite an intriguing prior set of experiments by Verfaillie and co-workers in which Spry's were identified as candidate markers of hematopoietic stem cells 15 . Through RNAi experiments, zebrafish Spry4 further was indicated to regulate blood cell development 15 ; and in murine gain-of-function experiments, Spry1 was suggested to modulate reconstitution of the hematopoietic system during bone marrow transplantation (possibly by affecting engraftment) 16 . In addition, Spred1 and -2 (as more distantly related orthologues of Sprys) 17 , recently have been implicated as mediators of eosinophilia and neutrophilia 18, 19 . For Spry2, epigenetic silencing interestingly has also been associated with B-cell lymphomagenesis 20 .
Through global transcriptome profiling of defined cohorts of developing murine bone marrow (pro)erythroblasts, we observed selective high-level expression of Spry1 during CFU-e to erythroblast development. This prompted us to study the role of Spry1 in hematopoiesis, and erythropoiesis, via a conditional Mx1-Cre mediated disruption of Spry1. As one finding observed at steady-state, Spry1 proved to be involved in normal erythroid homeostasis. Specifically, the loss of Spry1 in hematopoietic precursors led to reticulocytosis, and the engagement of splenic stress erythropoiesis. Following experimentally induced hemolysis, Spry1-deficient mice furthermore exhibited sustained, worsened anemia. This initially suggested positive erythropoietic roles for Spry1. In short-term bone marrow transplant experiments, Spry1-deficient donor cells also failed to efficiently reconstitute the erythron. In each anemia model, however, an over-expansion of proerythroblast progenitor pools was observed (together with an apparent faltering in progression to late-stage erythroblast formation). In related analyses, roles for Spry1 in modulating EPO-dependent phases of erythropoiesis were implicated. Specifically, via global PY-phospho-proteomic analyses, Spry1 was discovered to be a clear target for EPO/EPOR mediated PY-phosphorylation. Finally, within primary bone marrow proerythroblasts, Spry1-deficiency led to heightened EPO/EPOR activation of not only Erk1/2, but also Jak2. Collectively these data reveal novel non-redundant roles for Spry1 as an erythropoietic regulator; a new target of the EPOR; and a potential suppressor of Jak2 activity. Findings therefore may point to candidate actions of Spry1 within the contexts of polycythemia and additional myeloproliferative neoplasms 21, 22 .
For personal use only. on April 23, 2017 . by guest www.bloodjournal.org From
MATERIALS AND METHODS
Mouse, and anemia models-Mice harboring a floxed Spry1 allele were as detailed previously 23 , and were backcrossed to C57BL/6 mice for over ten generations. Mx1-Cre mice are a fully C57BL/6 background (Jackson Laboratories #005673). Cre expression was activated via poly dIdC dosing (22.5 mg/kg, 5 doses at 2 day intervals followed by a two-week no-treatment interval). Mice were studied at age 2 to 5 months. Control mice typically were Spry1 +/flox :Mx1-Cre (or if limiting, age-and sex-matched wild-type C57BL/6 mice). Steadystate peripheral blood cell populations were determined using an Advia 2120 hematology analyzer (Jackson Laboratory, Bar Harbor, ME). To generate a hemolytic anemia, mice were dosed with phenylhydrazine (75mg/kg, single intraperitoneal injection). In short-term bone marrow transplantations, 5x10 5 donor bone marrow were transplanted (retro-orbital injection) to irradiated B6 Ptprca recipients (450 RAD at 4 and 1 hours prior to transplant). Hematocrits and reticulocyte levels also were determined by capillary microcentrifugation, and thiazole-orange staining (via flow cytometry). BFU-e and CFU-e assays were as per manufacturer-defined protocols (Stem Cell Technologies). All procedures employed were approved by the IACUC of the Maine Medical Center Research Institute.
Primary hematopoietic cell preparations-Marrow from thoroughly cleaned femurs and tibiae was expelled into Iscove's modified Dulbecco medium (IMDM; Invitrogen, Carlsbad, CA) plus 2% bovine serum. Cells then were passed through 21 gauge needles and a 40 µm strainer, and resuspended in phosphate-buffered saline (PBS; Invitrogen, #14190-144). Prior to culture, red cells were lysed by exposure to buffered 0.8% ammonium chloride 24 . Washed cells were used to initiate cultures at 1.8×10 6 cells/mL in StemPro34 medium (Invitrogen) supplemented with 2.5 U/mL EPO (Epoietin-alpha, Amgen, Thousand Oaks, CA), 100 ng/mL murine stem cell factor (mSCF; Peprotech Rocky, Hill, NJ), 0.5 µM dexamethasone, 1.5 µM beta-estradiol, 75 µg/mL htransferrin (Sigma, St Louis, MO, #T-0665), 0.5% BSA (Stem Cell Technologies, #9300), 0.1 mM 2-mercaptoethanol, 1.5 mM L-glutamine (GIBCO),100 U/mL penicillin G, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B (GIBCO) (i.e., "SP34-ex" medium). At 24 and 48 hours, medium was refreshed [24] [25] [26] .
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Hybridizations were to Affymetrix 430-2.0 arrays (GeneChip scanner 3000, and GCOS software). GeneSpring software was used in data analyses (GC-RMA). Quantitative RT-PCR was performed as previously For personal use only. on April 23, 2017 . by guest www.bloodjournal.org From CA). A reduction in peak intensity in EPO-treated cells compared to control was expressed as a negative fold change value. All integrated peak intensity calculations also were manually reviewed to ensure proper integration of consistently shaped, co-eluting peaks. Changes in phosphorylated peptide levels were measured by taking the ratio of raw intensities between control and treated cells, with the untreated sample as the reference (denominator) in each case. Raw intensity ratios were normalized using a median adjustment technique whereby the log 2 ratios comprising each binary comparison (EPO-treated versus control) was independently and globally adjusted such that the normalized median log 2 ratio is zero. The normalized log 2 ratios were then converted to their corresponding normalized fold-changes.
Retroviruses-To prepare retroviruses, mSpry1 cDNA was first cloned to pMSCVneo, and a C-terminal inframe FLAG-tag cassette was added. The codon encoding Y53 (TAC) was then mutated to encode F53 (TTT).
Retroviruses encoding each were then prepared by transfection of Clontech GP2-293 cells with these templates, plus VSV-G encoding constructs 27 . Viruses were concentrated using Retro-Concentin reagent (SBI #RV100A-1, Mountain View, CA) and titered in NIH 3T3 cells. Viruses then were used to stably express Spry1
(Flag) and Spry1Y53F(Flag) in UT7epo cells 28 .
Western blotting and immunopreciptations -Cell extracts were prepared as recently detailed [24] [25] [26] .
Cleared extracts were assayed for protein content, denatured, electrophoresed, transferred to PVDF membranes and blotted. Primary antibodies were from Cell Signaling (Boston, MA,). As anti-Erk1,2 and anti-PT202, PY204, Erb1,2; anti-Jak2 and anti-PY1007, PY1008-Jak2; anti-Akt and anti-PS473Akt; anti-Stat5 and anti-Y694Stat5; anti-Stat1 and anti-Y701-Stat1; and anti-beta-tubulin. HRP-conjugated antibodies and ECL reagents were as described previously [24] [25] [26] . In immunopreciptations, Spry1(Flag) and Spry1-Y53(Flag)
were immunoprecipitated using Sepharose-immobilized anti-Flag epitope antibodies (Sigma, St Louis, MO) and eluted using a FLAG epitope peptide. In quantitative analyses of western blot signals, via Image-J software was used (http://rsb.info.nih.gov/ij/).
RESULTS

Spry1 is highly expressed in developing (pro)erythroblasts, and conditional Spry1 deletion activates reticulocytosis plus splenic erythropoiesis
In the course of investigating the in vivo actions of EPO 24- Figure S1 ). When these subpopulations were isolated and subjected to expression array profiling, a strong and developmentally sustained expression of select signal transduction factors was apparent including Spry1. By comparison, no other Spry genes were expressed at elevated levels within these bone marrow (pro)erythroblasts ( Figure 1A ). Mining of extant transcriptome databases further showed that Spry1 levels were depressed in (erythro)megakaryocytic cells from Gata1-knockdown mice 30 suggesting a role for Gata1 in Spry1 expression ( Figure 1B) . Within a series of human CD34-derived developing erythroid progenitors 31 , Spry1 levels also were observed to be maximal at an erythroblast stage ( Figure 1C ). (Figure 2A ).
At steady-state, Spry1 deletion did not lead to major skewing of myeloid of lymphoid peripheral blood cell populations, but did selectively elevate reticulocyte counts ( Figure 2B , Supplemental Figure 2C ). Levels of splenic stage-E2 proerythroblasts also were elevated by ~170% ( Figure 2D ). Possible effects on Epo expression levels also were assessed via quantitative RT-PCR of kidney Epo levels 32 . Levels in conditional Spry1-null mice were elevated 2.1 fold (+/-0.3, n=4). This suggested selective modest roles for Spry1 during steady-state erythropoiesis. BFU-e and CFU-e levels within bone marrow of control vs Spry1-deleted mice, however, did not differ significantly at steady-state (Supplemental Table S -2). In Mx1-Cre conditional Spry1-null mice, an apparent trend of increased platelet levels also was observed (Supplemental Table S To better assess intrinsic properties of Spry1-deficient erythroid progenitors in the absence of hemolysis and oxidative stress, bone marrow transplant experiments were performed using marrow from Spry1-deleted vs control mice. At a time-point when hematocrits were largely restored in irradiated recipients by transplanted control donor cells (day 16), hematocrits in mice transplanted with Spry1-deficient bone marrow failed to efficiently rebound ( Figure 4A ). In particular, recoveries in red cell mass were limited to ~54% of wild-type controls. In these experiments, relative frequencies of Kit neg CD71 high Ter119 neg stage-E2 proerythroblasts also were analyzed within spleens of transplanted mice. Notably, E2 proerythroblasts, proved to be overrepresented ( Figures 4C,4D ). This heightened frequency of splenic E2 cells (and to some extent E1 progenitors) also was reflected by observed increase in absolute numbers within spleens of recipient mice (see Supplemental Table S -3, lower panel). This further suggested that Spry1-deficiency also might dysregulate proerythroblast expansion (and that sustained hyper-expansion might limit conversion of these cells to late stage E3 erythroblasts).
In an aim to assess possible effects of Spry1-deletion in erythroid progenitor cells (EPC's), at a cellular level,
we also employed an optimized ex vivo expansion (and development) system for murine bone marrow EPC's 25 . Specifically, control and conditional Spry1-null EPC's were expanded (from bone marrow), and whether Spry1-deficiency might affect cell survival and/or cell cycle properties then was assessed. For survival potential, no advantages (or disadvantages) were detected among E1 or E2 EPC's (using YoPro3 as a sensitive agent for detecting compromised cells). Spry1-deficient stage E3 erythroblasts, however, exhibited moderately compromised survival profiles (see Supplemental Figure S-3) . These results suggest that within this late EPC compartment Spry1 may exert at least limited pro-survival effects.
EPOR mediates rapid phosphorylation of Spry1 at Y53, and Spry1-deficiency potentiates Erk1/2 plus Jak2 activation
Taken together, the above studies suggested that one action of Spry1 might be to limit erythroid progenitor expansion during anemia (in both bone marrow, and spleen). Within RTK receptor systems, Spry action depends upon the induced phosphorylation of a conserved N-terminal tyrosine 53 residue 33 . This especially is established for the FGFR 1-3 . FGF's previously have been reported to modulate hematopoiesis 34 , and perhaps erythroid development 35 . In transcriptome-based analyses of possible FGFR expression among stage E1, E2
and E3 (pro)erythroblasts, however, expression was very limited (to undetectable) ( Figure 5A ). Based on the dependency of late CFU-e and proerythroblasts for EPO, we next investigated whether Spry proteins might represent targets for EPOR/Jak2-mediated tyrosine phosphorylation. To provide residuespecific insight, an LC/MS-MS approach was applied (as outlined in Figure 5B ). To provide sufficient cells for such analyses, EPO-dependent erythromegakaryocytic UT7epo cells were used. In these analyses (and for independent duplicate samples), Spry1 proved to be modulated in its Y53 phosphorylation >5.5-fold within 15 minutes of EPO exposure ( Figure 5C , Supplemental Figure S-4 , and Supplemental Figures 5B, 5C, 5D ). By direct comparison (and as validating examples), tyrosine phosphorylation of Jak2 was observed (in duplicate) at each of five known sites. As a known EPO/EPOR-regulated adaptor, Gab2 tyrosine phosphorylation was also observed to be induced at Y643, Y614, and Y476 ( Figure 5D ). To validate mass spectrometry data, Spry1 was epitope-tagged (C-terminus FLAG tag) and cloned to pMSCVneo. This pMSCVneo-Spry1(FLAG) template was used to prepare VSV-G packaged retroviruses, which were then stably transduced and Based on the discovery that ligated EPOR/Jak2 complexes activate Spry1, the prospect that Spry1 might affect Jak2 next was tested using primary proerythroblasts from conditional Spry1-deficient vs. control mice.
Specifically, bone marrow-derived erythroid progenitors were expanded for a limited interval. Lin pos cells then were depleted. Following a 5 hour period of HGF-withdrawal, cells were challenged with EPO (1 U/mL) for 0, 8
For personal use only. on April 23, 2017 . by guest www.bloodjournal.org From 13 and 24 minutes. Levels of Jak2, Erk1,2 and Akt activation then were determined by western blot analyses (using antibodies to PY-1007, 1008-Jak2; PT-202 PY-204 Erk1,2; and PS-473 Akt). Notably, within Spry1-deficient cells, Jak2 was activated by EPO at cumulative levels approximating 400% of control levels ( Figure   6A ). By direct comparison, no marked differential in activation was observed for Akt. EPO-induced phosphorylation of Erk1,2, however, proved to be sustained. When Stat5 was analyzed, an apparent modest increase in PY-phosphorylation was observed due to Spry1 deletion, and a second molecular species of PYStat5 also was clearly generated (see Supplemental Figure S-7) . Therefore, within primary bone marrow erythroid progenitors, Jak2 is proposed to be subject to suppression by Spry1 ( Figure 6B ). Decreases in Spry1 expression therefore are suggested to lead to a dysregulation of erythroid progenitor expansion ( Figure 6C ), especially during anemia. During late-stage erythroblast differentiation, positive roles for Spry1 also may exist.
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DISCUSSION
For the presently reported findings, significance resides in three prime contexts. First, among four Spry genes, Spry1 is selectively highly expressed in developing primary bone marrow (pro)erythroblasts. Second, via a conditional loss-of-function approach, Spry1 is indicated to be functionally important in regulating balanced levels of erythroid progenitors vs. differentiating erythroblast progeny, especially during anemia. In particular, deletion of Spry1 predominantly may dysregulate the expansion of proerythroblasts at the apparent expense of their advanced development. Third, a new connection is forged among the EPOR, Jak2, and Spry1 in which Spry1 comprises a strong target for EPOR/Jak2 directed PY53 phosphorylation; and acts (at least in part) in a negative feedback mode to inhibit Jak2 within activated EPOR complexes. These major aspects are discussed in further detail below. Possible implications for Spry's with hematological disease contexts also are considered.
With regards to regulators of Spry expression, analyses in non-hematopoietic tissues previously have described strong expression of Spry's in FGF-responsive tissues [1] [2] [3] 36 , and FGFR and RTK induction of Spry genes has been described 37 . Regulation of Spry gene expression, however, is obviously more complex. In kidney, for example, Spry 1, 2 and 4 are expressed mainly in epithelial cells 36 , and within uteric buds Spry1 is predominant 23, 36 . In contrast, during tooth development Spry2 and Spry4 expression become restricted to epithelium and mesenchyme, respectively 6 . Presently, Spry1 is shown to be selectively expressed at high levels in developing bone marrow derived erythroid progenitors and (pro)erythroblasts. In silico analyses also suggest roles for Gata1 as a possible regulator in that Gata1 knockdown leads to a several-fold decrease in For
of Spry1 proved to affect only erythroid cells. Specifically, this involved reticulocytosis together with an activation of splenic erythropoiesis. This reticulocytosis did not lead to elevated hematocrits: Underlying factors might include effects on red cell half-life due to stress erythropoiesis production in the absence of Spry1, and/or possible hemolysis. During stress, Spry's can play extended roles [38] [39] [40] . Spry4 (for example) has recently been characterized as a hypoxia-response factor 41 . In keeping with this concept, erythropoietic roles for Spry1 became obvious during anemia. This included impaired red cell formation due to Spry1 deletion as observed during both hemolytic anemia, and the anemia of short-term bone marrow transplantation. For hemolytic anemia, both severity and duration were affected. Essentially normal hematocrits, however, were ultimately restored. In phenylhydrazine and bone marrow transplant experiments, apparent increases in splenic erythroid progenitor populations among Spry1-null mice did not translate to increased erythrocyte levels. This might be attributable to heightened apoptosis among Spry1-null stage E3 erythroblasts, or potential effects of Spry1-deficiency on macrophage and blood island formation. Following bone marrow transplant, recipient mice also recovered when transplanted with Spry1 -/-donor marrow (but at markedly delayed rates) (data not shown). Results of bone marrow transplant experiments, in addition, indicate erythroid cell-intrinsic roles for Spry1. In future experiments, whether rebound effects might reflect heightened contributions of known stress erythropoiesis mechanisms (eg., glucocorticoids or BMP4) 42, 43 , or possible compensating effects of other Spry's (or Spred's) 17 will be of interest to discover. In the present studies, From our in vivo and ex vivo analyses, Spry1 might also be suggested to limit the expansion of erythroid progenitor pools, and to perhaps also promote late-stage erythroblast development. The prior case derives from an observed hyper-expansion of CFUe-like progenitors as well as proerythroblasts among Spry1-deficient cells in anemia contexts. At steady-state, BFU-e and CFU-e levels were not significantly skewed due to Spry1 deletion. In addition, no apparent survival advantage was obvious among Spry1-null progenitors (data not shown). Proerythroblast hyper-expansion therefore is proposed to result from sustained activation of [1] [2] [3] . Consistent with the ability of Spry1 to attenuate a Raf/Mek/Erk axis [1] [2] [3] 5, 7, 9 , sustained activation of Erk1,2 also was presently observed in Spry1-deficient erythroid progenitors. Akt, in contrast, was not markedly affected. Notably, for a knocked-in PY-deficient EPOR allele (EPOR-HM), enhanced coupling selectively to Mek1 and Erk1,2 (but not Akt) also was observed, and similarly associated with dysregulated erythroblast development 44 . Consistent with this proposed feedback loop, Spry1 was discovered in UT7epo cells to be a major target for EPO/EPOR mediated Y53 phosphorylation (see Figure 5 ). Whether this is mediated directly by EPOR/Jak2, or possibly downstream PTK's is not yet resolved.
The present findings are novel in that to our knowledge Spry's have not previously been associated with erythropoiesis, EPO/EPOR action or Jak kinase activity. With regards to Jak2 regulation, mechanisms engaged by Spry1 are of significant interest to consider based on Jak2 kinase mutations in myeloproliferative disorders, and polycythemia 21, 22 . Molecular mechanisms for Spry1 suppression of Jak2 presently are speculative. Based on previously reported Spry partners, two rational candidates are Cbl and Shp protein tyrosine phosphatases [1] [2] [3] [11] [12] [13] . If Spry1 sequestered Cbl, however, one prediction might be a more global activation of EPOR signaling, including Akt. Shp-1 and/or -2 are perhaps attractive candidates in that Shp protein tyrosine phosphatases previously have been shown to inhibit Jak2 45, 46 (and to bind Spry at a conserved cysteine-rich domain) 3, 13 . Other potential routes also exist. Grb2 (for example) binds Spry's 3, 14 , and Grb2 recently has been suggested to be involved in Shp1 (and SOCS1) inhibition of Jak2 47 . In a related vein, it's noteworthy that decreases in Spry2 levels have been associated with B-cell lymphomagenesis 20 . Here, IL7R-Jak kinase circuits might also merit consideration. Future investigations will seek to specifically define molecular mechanisms of Spry1 inhibition of Jak2. 
AUTHORSHIP CONTRIBUTIONS
Efforts associated with the generation and maintenance of mouse models were contributed by P. 
DISCLOSURE OF CONFLICTS OF INTEREST
The authors declare no competing financial interests. 31 (and GEO Accession GDS2431). 
